Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice

Richard W. Joseph, Gurkamal Chatta, Ulka Vaishampayan

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Background Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. Methods and Purpose This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.

Original languageEnglish (US)
Pages (from-to)142-148
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Issue number4
StatePublished - Apr 1 2017


  • Advanced renal cell carcinoma
  • Immune checkpoint inhibitor
  • Immunotherapy agents
  • Nivolumab
  • PD-1 inhibitor
  • Second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice'. Together they form a unique fingerprint.

Cite this